Redefining Equine Health
A Breakthrough Solution for Laminitis
The company’s team
is a collaboration of consultants and professionals
PTP-102
has patents pending for Europe, US and Australia
Mission statement
At Byrock Technologies our mission is to support veterinarians, owners and the equine industry in their task to improve the health of horses worldwide.
Quality:
At Byrock Technologies, we uphold stringent standards in pharmaceutical development. Our flagship product, PTP-102, has successfully advanced through proof of concept studies, demonstrating significant potential to enhance equine health effectively and safely.
Teamwork:
Our success is driven by collaborative efforts to fulfil our mission. Our multidisciplinary team combines deep scientific insight with extensive legal expertise to craft innovative solutions for equine health challenges.
Innovation:
Driven by a mission to address critical gaps in equine healthcare, our team is at the forefront of pioneering treatments that merge scientific advancement with market demands. PTP-102 represents the first step in Byrock’s journey to disrupt the equine healthcare market.
